Medgenics Inc Admission of Shares to AIM (6956W)

TIDMMEDG TIDMMEDU

RNS Number : 6956W

Medgenics Inc

30 January 2013

 
Press Release  30 January 2013

Medgenics, Inc.

("Medgenics" or the "Company")

Admission of Shares to AIM

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump(TM) , a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that on November 1, 2012 it entered into an agreement with Corporate Profile LLC to provide consultancy services and advice to the Company with regard to investor relations and media. Part of the consideration for such services was the issuance of 30,000 restricted common shares which have been issued and allotted conditional upon admission to trading on AIM.

On December 1, 2012 the Company also entered into an agreement with Platinum VIII Investments and Media LLC ("Platinum") to provide consultancy services and advice to the Company with regard to investor relations and media. Part of the consideration for such services was the initial issuance of 25,000 restricted common shares which have been issued and allotted conditional upon admission to trading on AIM and an additional issuance of 5,000 restricted common shares to Platinum each month for the next 5 months.

Application has been made to the London Stock Exchange for these issued restricted common shares to be admitted to trading on AIM and admission is expected to commence on or around February 4, 2013.

- Ends -

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis and hemophilia, among others. For more information, visit the Company's website at www.medgenics.com.

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend, " "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

For further information, contact:

 
      Medgenics, Inc.                        Phone: +972 4 902 8900 
       Dr. Andrew L. Pearlman 
       Andrew.pearlman@medgenics.com 
      Abchurch Communications                Phone: +44 207 398 7719 
       Adam Michael 
       Joanne Shears 
       Jamie Hooper 
       jamie.hooper@abchurch-group.com 
      Nomura Code Securities (NOMAD/Broker)  Phone: +44 207 776 1219 
       Jonathan Senior 
       Giles Balleny 
      SVS Securities plc (Joint Broker)      Phone: +44 207 638 5600 
       Alex Mattey 
       Ian Callaway

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAFFEDEFDEFF

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024